Company presentation november, 2019 - cloudfront.net
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Company Presentation November, 2019
Forward looking statements:
This document has been prepared for informa- terminology. These forward-looking statements are not
tional purposes only. This document contains guarantees of future performance and by their nature
summary information about Brain Scientific Inc. (“Brain involve known and unknown risks and uncertainties that
Scientific”), does not purport to be complete, and no may cause actual opportunities, prospects, performance
representations or warranties about such information are and results to vary from those presented in this document,
made by Brain Scientific or its representatives. and those variances may be material. In evaluating
such statements, prospective investors should carefully
This document does not constitute an offer to sell or a consider the various risks and uncertainties identified
solicitation of an offer to purchase any securities of Brain in Brain Scientific’s public filings with the Securities and
Scientific. Any such offer will be made only pursuant to Exchange Commission, such as market risk, liquidity risk,
an effective registration statement or an exemption from competitive risk, regulatory risk and other commonly
registration. recognized forms of risk relating to Brain Scientific and
its securities. In light of these risks, uncertainties and
This document contains forward-looking statements
assumptions, the forward-looking events discussed in
relating to future events or the future financial
this document might not occur. Brain Scientific is not
performance and operations of Brain Scientific. Forward-
obligated to publicly update or revise any forward-looking
looking statements, which involve assumptions and
statements, whether as a result of new information, future
describe Brain Scientific’s intent, belief or current
events or otherwise.
expectations about its business opportunities, prospects,
performance and results, are generally identifiable by No independent party has audited the forecasts, if any, set
use of the words “may,” “could,” “should,” “will,” “would,” forth herein, nor has any independent party undertaken
“expect,” “anticipate,” “plan,” “potential,” “estimate,” to confirm that any hypothetical performance or other
“believe,” “intend,” “project,” “forecast,” the negative of performance that may be set forth herein adheres to the
such words and other variations on such words or similar assumptions or conditions specified herein.
2
Who we are Technology
Brain Scientific is a commercial- Development of technologies including:
stage company offering products
and solutions related to the brain Phase I Phase II Phase III
including neurology, AI and 2018–2019 2020 2021–22
machine learning.
Founded in 2015 as an extension
of Brain Rx, a pre-Alzheimer
diagnostic company. Portable, clinical-grade, Secure, cloud-based, Artificial Intelligence
easy-to-use neurological highly scalable infrastruc- assisted diagnostic analy-
diagnostic devices. ture to transmit sis to increase neurologist
Headquartered in New York. patient data between efficiency, consistency
neurologists and patients. and accuracy.
Went public in September,
2018 (BRSF)
Intellectual Property: 3 patents in Us, China, and Europe
3
NeuroCaptm
• NeuroCapTM, a PATENTED
disposable EEG headset
with 22 pre-gelled electrodes
following the international
10–20 system.
• Easy Setup.
• FDA cleared in 2018.
4
NeuroEEGtm
• NeuroEEGTM, a PATENTED portable,
wireless, 16-channel amplifier.
• Fits in the palm of your hand.
• Can easily be deployed across
broad spectrum of patient settings.
• User-friendly intuitive NeuroEEGTM
Software™ requires minimal
training.
• FDA cleared in 2018.
5
EEG INDUSTRY LIMITATIONS
Current EEG procedure is slow, expensive and cumbersome
• Specialized EEG technologists are needed
• Bulky equipment
• Specialized neurologists are needed to read the EEG data
Seizure Treat while EEG tech Neurologist
suspicion waiting arrives interprets
for EEG EEG result
from 1 to 24 hours
1 2 3 4 5 6 7
from 2 to 48 hours
EEG order Record EEG Treatment based
on EEG results
6Brain Scientific EEG Solution
Setup Recording Analysis
Proprietary disposable Pocket-sized EEG Cloud EEG Reading.
headband can be set up with all the functionality Raw EEG data is in-
by anyone within 5 min. of the conventional EEG. stantly transferred to a
server for access and
interpretation by EEG
trained neurologist for
formal diagnosis.
7NeuroCap™ Benefits
• Fixed Pre-Gelled Electrodes
allow any clinical personnel
(nurse, medical assistants) to
apply EEG in 5 minutes or less.
• Disposable Headset eliminates
patient’s exposure to infection
and the need to sanitize elec-
trodes after each use.
• 3rd party compatibility allows
NeuroCapTM to work with conven-
tional EEG amplifiers in use.
8NeuroEEG™ Benefits
• Low-cost, Portable and
Wireless amplifier provides
the same quality of signal as
conventional EEG devices.
• Assists in automated seizure
detection with the ability for
EEG data to be reviewed in
real-time and post hoc.
• Cost savings vs. conventional
amplifiers.
9Customer Benefits
✓ Reduced hospital operational and administrative costs by substituting
technology for technicians.
✓ Expansion of EEG coverage to rural areas enabling hospitals to
provide 24/7 monitoring during late nights and weekends.
✓ Enhanced patient retention, eliminating outpatient referral, as
hospitals implement low-cost, easy to use EEG monitoring on-site.
✓ Remote data review and evaluation as neurologists access patient
data through 3rd party software integration with Persyst or Citrix.
✓ Reduction of hospital-acquired infections.
10Target Markets
• Urban Emergency Depart-
ments and Intensive Care Units
Tertiary Care • Community / Rural Hospitals
• Neurologist Practice
Ambulatory Care • Primary Care / Internal Medicine
• Pain Management Clinics
Independent Diagnostic • Sleep Labs
Testing Facilities (IDTF) • Nursing Homes
• Mobile Clinics
11Urban ED and ICU
Millions of patients in US hospitals can have seizures and will benefit from instant EEG.
Emergence Department ICU
130,000,000 ED visits
per year in the US
10,000,000 AMS 5,600,000 ICU
(Altered Mental Status) patients per year
~ 5,000,000
4,000,000 1,000,000 patients will
subject subject
to seizure1 to seizure1 be candidates
for EEG tests
NCSE Non-Convulsive Status Epilepticus NCSE
>>65,000 NCSE patients currently diagnosed in the US per year.
With EEGs being more accessible, this number is expected to rise significantly.
1. Include head trauma patients (2.1 Mn ED visits), stroke patients (800,000 ED visits), and epilepsy related ED visits (1Mn), brain tumor or infection 12Community / Rural Hospitals
and Neurologist Practice
Community / Rural Hospitals Neurologist Practice
Only 254 of 6210 US hospitals are 16,000 Neurologists in US,
Level 4 Epilepsy centers approximately 3000 are Epileptologists,
that have 24/7 EEG coverage less than 1000 are pediatric neurologists
Very few non Level 4 Epilepsy centers have All are incentivized in some way to increase
24/7 EEG tech coverage revenue and expand services, including EEG
Opportunity to extend much needed EEG Brain Scientific provides easy way to in-
services to over 5900 hospitals with lower crease billing and expand services at both
cost amplifier and disposable EEG cap the hospital and within practices
www.naec-epilepsy.org/about-epilepsy-centers/find-an-epilepsy-center/all-epilepsy-center-locations 13GO-TO Market Strategy
Combine EEG
Partner with
Bundle dispos- diagnostic
industry leaders
Leverage Integrate our able EEG + hardware
in EEG manu-
relationships EEG solution respiratory with PainQx
facturing and
with medical with existing equipment pain predictive
distributors to
distributors telemedicine to service the algorithms to
service national
and GPOs platforms growing sleep service the
and global EEG
market pain manage-
market
ment market
14Competitive Landscape
Disposable Cap
+ + – +
Portable
+ + + +
Integrated Software
+ + + +
Compatibility with
other EEG products + + – –
Teleneurology
Enablement + – – +
Reduced Depen-
dence on EEG techs + + + +
AI assisted analysis
+ – – –
15Product Roadmap
Developing product line extensions to address new, growing markets:
Pediatric and Long-Term Monitoring.
Long-Term Artificial
Pediatric EEG
Routine EEG Monitoring Intelligence
Caps
Pediatric Adults
New products for New products for New products for New products for
Routine market: Pediatric market: LTM market (24+ hours): AI market:
NeuroCap-8 NeuroCap-8 Pediatric NeuroCap-8-Adult Brain E-Tattoo
(with 8 channels)
NeuroCap-19-Adult Brain AI: Neural Network
enabled predictive
NeuroCap-8 Pediatric
capabilities for brain
NeuroEEG Amplifier health / disease
(24 channels) progression
16BRAIN E-TATTOO:
SUBCUTANEOUS
IMPLANTABLE
EEG ELECTRODE
• 4 channels
• Designed for long-term
monitoring to detect epileptic
seizures
• Minimally invasive implantation
• Better EEG signal quality and
sensitivity
17Building Brain AI
database of biomarkers
• Creating a database of normal and abnor-
mal brains for detecting seizures and de-
mentia
• Developing algorithms to detect epilepsy,
memory dementia, pre Alzheimer’s diag-
nostics
• AI and Machine learning process to see ab-
normal activity on a big database
Working with current databases
October, 2019: 1st stage of development
a machine learning algorithm for epilepsy
(600 patients)
18Milestones 2020
Q1 Q2 Q3 Q4
US manufacturing; EEG distribution in Natus commercial Complimentary market
re-optimized NeuroCap combination with launch launches — geographic;
commercial release respiratory sleep kits indication
Canada Healthcare
Cadwell strategic Premier Inc. (GPO) market initiation Africa and Asia health-
partnership, widescale commercial distribu- care
FDA validation study —
US distribution tion
PainQX, EEG pain Stroke
Concussive data collec- CE marking; EU market detection algorithms
Pain management
tion — NCAA Division I rollout
National teleneurology
athletes, Virginia Tech
coverage rollout
Persyst software integra-
tion — seizure detection,
remote data
19BRAIN SCIENTIFIC’S TEAM
Dr. Baruch (Boris) Goldstein, PhD Street Research and, prior to that, Greg Juffer, Chief Commercial Officer ny’s Quality Management System,
Co-Founder & Executive Chairman was a Co-founder of the Healthcare Mr. Juffer is an experienced director and oversee clinical evaluations of
With over 30 years’ experience in re- Investment Banking group at Gil- of sales with established relation- EEG solutions across US and global
lated fields, Dr. Goldstein has built ford Securities. Prior to joining Gil- ships with hospitals and medical healthcare markets.
and scaled numerous high-tech and ford, Dr. Kukekov was a Managing distributors. He brings more than 20
security companies in Silicon Valley Director at Paramount BioCapital, years experience in sales in the Medi- Irina Nazarova, Director of Marketing
and internationally. Dr. Goldstein also where he ran the advisory, M&A and cal Device & Services, Pharmaceuti- Ms. Nazarova is a media profession-
brings over two decades of experi- capital raising services for in-house cal, Biotech, and Neurology markets. al with an extensive background in
ence in neuro-net informatics, brain private and public portfolio compa- Previously, Mr. Juffer managed direct journalism, specializes in Digital Mar-
image recognition and processing, nies. Dr. Kukekov holds a number sales reps and distributor relation- keting, Partnerships, Content Mar-
artificial intelligence and manage- of research scholarship awards and ship with 100 sales reps nationwide. keting, and Public Relations.
ment of robotic systems. peer review publications.
Abdus-Salaam Muwwakkil, Medical Advisory Board
Chief Quality Officer
Dr. Nikolay Kukekov, PhD Vadim Sakharov, CTO John Gaitanis, M.D.,
Director Experienced executive across health-
Mr. Sakharov has over 25 years of Chief of Pediatric Neurology,
care technology sector for product
Nickolay V Kukekov, Ph.D. is a Part- experience in research and applied Tufts Medical Center
development, regulatory affairs,
ner at HRA Capital. Prior to form- engineering culminating in over 70 and operations. Secured company’s John Hixson, M.D.,
ing HRA Capital, Dr. Kukekov was published research papers. Received 510(k) clearances and compliance Associate Professor Neurology,
Managing Director of Healthcare PhD and BSc from Taganrog State with FDA and cGMP requirements. University of California,
Investment Banking at Summer Radiotechnical University. Responsible to implement compa- San Francisco
20Thank you! info@memorymd.com www.brainscientific.com
You can also read
